Immunotherapy News and Research

Latest Immunotherapy News and Research

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.

28 Dec 2010

Biogen Idec acquires Neurimmune subsidiary

Biogen Idec and Neurimmune Holding AG today announced that Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three central nervous system (CNS) targets: alpha-synuclein, tau and TDP-43.

21 Dec 2010

CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer

CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.

16 Dec 2010

$Phase 1b clinical trial of JX-594 in metastatic, refractory colorectal cancer commences in Korea$

Phase 1b clinical trial of JX-594 in metastatic, refractory colorectal cancer commences in Korea

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that enrollment and treatment of patients in a Phase 1b clinical trial has been initiated to evaluate JX-594 in patients with advanced metastatic, refractory colorectal cancer (CRC).

16 Dec 2010

Angiogenesis inhibition is a validated strategy for cancer therapy

Scientists at the Dana-Farber Cancer Institute may have uncovered a mechanism for blocking tumor angiogenesis that involves the patient's immune system, according to findings published in Cancer Research, a journal of the American Association for Cancer Research.

15 Dec 2010

CRI introduces new model of philanthropic investment to improve cancer patient care

Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization established in 1953 to advance the science of tumor immunology and foster the discovery of new cancer immunotherapies, announced today the launch of the Cancer Vaccine Acceleration Fund (CVAF), a new model of philanthropic investment and academic-industry collaboration established in partnership with the Ludwig Institute for Cancer Research Ltd (LICR) to speed the clinical development of therapeutic cancer vaccines and other immune system-based therapies.

15 Dec 2010

Tolerx commences TRX518 Phase 1 trial in malignant melanoma

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.

14 Dec 2010

CEL-SCI reports net income of $10.48M for fiscal 2010 vs. $40.9M loss for fiscal 2009

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2010.

13 Dec 2010

Novelos NOV-002 demonstrates positive results in Phase 2 neoadjuvant breast cancer trial

Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer, announced that today a poster highlighting positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer is being presented by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine at the AACR Breast Cancer Symposium in San Antonio, TX.

13 Dec 2010

Argos' AGS-004 shows feasibility in in vitro models to generate DC from viremic patients

Argos Therapeutics announced today that its Arcelis HIV immunotherapy, AGS-004, showed feasibility in in vitro models to generate fully functional dendritic cells (DC) from viremic patients.

13 Dec 2010

Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results

Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.

10 Dec 2010

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

Memgen, LLC announced the presentation of clinical and preclinical results for its lead product, ISF35, during the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The research and clinical development of ISF35 announced today was led by Januario Castro, MD, and Thomas Kipps, MD, PhD, both at the University of California, San Diego.

10 Dec 2010

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

A La Jolla Institute team, led by leading type 1 diabetes researcher Matthias von Herrath, M.D., has demonstrated the effectiveness of a recently developed computer model in predicting key information about nasal insulin treatment regimens in type 1 (juvenile) diabetes. Development of the software, the Type 1 Diabetes PhysioLab- Platform, was funded through the peer-reviewed grant program of the American Diabetes Association.

9 Dec 2010

Immunomedics reports CD22 antibody produced significant anti-tumor response

Immunomedics, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that epratuzumab, the Company's humanized anti-CD22 antibody, conjugated with SN-38, the active component of irinotecan, produced significant anti-tumor responses in a mouse model of human lymphoma.

8 Dec 2010

Phase 1 study results of Aduro BioTech's CRS-207 presented at AACR Conference on Tumor Immunology

Aduro BioTech, a clinical-stage immunotherapy company, is pleased to announce the presentation of the CRS-207 Phase 1 study at the AACR Special Conference on Tumor Immunology in Miami, Florida by the Principal Investigator, Dr. Dung Le of the Johns Hopkins Kimmel Cancer Center. Dr. Le reported that CRS-207 intravenous administration was well tolerated in subjects with advanced, treatment-refractory cancers. Dr. Le also reported evidence of immune activation and that 6 out of 17 end-stage cancer patients lived 15 months or longer.

7 Dec 2010

Lytix Biopharma, KAEL-GemVax initiate treatment in LTX-315/GV1001 combination anti-cancer vaccine trial

The Norwegian biopharmaceutical company Lytix Biopharma and the Korean biotechnology company KAEL-GemVax announced today the successful first treatment in the study of a combination of LTX-315 and GV1001 as anti-cancer vaccine therapy.

7 Dec 2010

Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

Xencor, Inc. and MorphoSys AG announced today that they have initiated Phase 1 testing for XmAb®5574 (MOR208), and the first patient has been dosed. XmAb5574 (MOR208) is a potent monoclonal anti-CD19 antibody to which MorphoSys recently gained worldwide access via an exclusive license and collaboration agreement with Xencor.

2 Dec 2010

Tolerx enters collaborative research agreement with Cancer Research Institute

Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.

2 Dec 2010

Physician-scientists enroll patients with NSCLC cancer in MAGE-A3 Phase III trial

An experimental immunotherapy may someday become the newest weapon against lung cancer. Physician-scientists from Weill Cornell Medical College and Columbia University Medical Center are enrolling patients with non-small cell lung cancer (NSCLC) at NewYork-Presbyterian Hospital as part of an ongoing Phase III trial.

1 Dec 2010

Argos commences dosing in Arcelis personalized immunotherapy Phase 2b clinical trial for HIV

Argos Therapeutics today announced that it has initiated dosing of patients in a Phase 2b clinical trial of its Arcelis™ personalized immunotherapy for the treatment of HIV patients, AGS-004.

30 Nov 2010

Immunotherapy News and Research

Latest Immunotherapy News and Research

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Biogen Idec acquires Neurimmune subsidiary

CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer

Phase 1b clinical trial of JX-594 in metastatic, refractory colorectal cancer commences in Korea

Angiogenesis inhibition is a validated strategy for cancer therapy

CRI introduces new model of philanthropic investment to improve cancer patient care

Tolerx commences TRX518 Phase 1 trial in malignant melanoma

CEL-SCI reports net income of $10.48M for fiscal 2010 vs. $40.9M loss for fiscal 2009

Novelos NOV-002 demonstrates positive results in Phase 2 neoadjuvant breast cancer trial

Argos' AGS-004 shows feasibility in in vitro models to generate DC from viremic patients

Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

Immunomedics reports CD22 antibody produced significant anti-tumor response

Phase 1 study results of Aduro BioTech's CRS-207 presented at AACR Conference on Tumor Immunology

Lytix Biopharma, KAEL-GemVax initiate treatment in LTX-315/GV1001 combination anti-cancer vaccine trial

Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

Tolerx enters collaborative research agreement with Cancer Research Institute

Physician-scientists enroll patients with NSCLC cancer in MAGE-A3 Phase III trial

Argos commences dosing in Arcelis personalized immunotherapy Phase 2b clinical trial for HIV

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Immunotherapy News and Research

Latest Immunotherapy News and Research

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in